CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 63 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $515,693,234 | -31.0% | 23,623,144 | +0.6% | 0.04% | -28.6% |
| Q2 2023 | $746,867,552 | -34.8% | 23,493,789 | -49.9% | 0.06% | +21.2% |
| Q1 2023 | $1,144,732,864 | +55.0% | 46,934,516 | +100.4% | 0.05% | -28.8% |
| Q4 2022 | $738,576,334 | +12.1% | 23,417,132 | +0.4% | 0.07% | +5.8% |
| Q3 2022 | $658,898,000 | +12.0% | 23,315,565 | +4.8% | 0.07% | +16.9% |
| Q2 2022 | $588,116,000 | -24.3% | 22,243,384 | +0.2% | 0.06% | -4.8% |
| Q1 2022 | $777,363,000 | +22.9% | 22,204,001 | +13.8% | 0.06% | +31.9% |
| Q4 2021 | $632,508,000 | +14.0% | 19,509,813 | +3.7% | 0.05% | +6.8% |
| Q3 2021 | $554,796,000 | +145.0% | 18,806,629 | +112.8% | 0.04% | +144.4% |
| Q2 2021 | $226,406,000 | +222.5% | 8,837,061 | +72.9% | 0.02% | +200.0% |
| Q1 2021 | $70,193,000 | -1.9% | 5,112,400 | +18.5% | 0.01% | 0.0% |
| Q4 2020 | $71,521,000 | – | 4,313,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |